Novartis AG
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic … Read more
Market Cap & Net Worth: Novartis AG (NVSEF)
Novartis AG (PINK:NVSEF) has a market capitalization of $199.73 Billion ($199.73 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #78 globally and #64 in its home market, demonstrating a -2.68% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Novartis AG's stock price $104.67 by its total outstanding shares 1908151679 (1.91 Billion).
Novartis AG Market Cap History: 2015 to 2025
Novartis AG's market capitalization history from 2015 to 2025. Data shows growth from $101.00 Billion to $199.73 Billion (6.48% CAGR).
Novartis AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Novartis AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.50x
Novartis AG's market cap is 3.50 times its annual revenue
0.84x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
13.63x
Novartis AG's market cap is 13.63 times its annual earnings
11.15x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $87.96 Billion | $49.44 Billion | $6.71 Billion | 1.78x | 13.10x |
| 2017 | $106.98 Billion | $50.13 Billion | $7.70 Billion | 2.13x | 13.89x |
| 2018 | $110.63 Billion | $53.17 Billion | $12.61 Billion | 2.08x | 8.77x |
| 2019 | $146.35 Billion | $48.68 Billion | $11.73 Billion | 3.01x | 12.47x |
| 2020 | $150.31 Billion | $49.90 Billion | $8.07 Billion | 3.01x | 18.62x |
| 2021 | $145.60 Billion | $52.88 Billion | $24.02 Billion | 2.75x | 6.06x |
| 2022 | $159.40 Billion | $51.83 Billion | $6.96 Billion | 3.08x | 22.92x |
| 2023 | $190.82 Billion | $46.66 Billion | $14.85 Billion | 4.09x | 12.85x |
| 2024 | $195.97 Billion | $51.72 Billion | $11.94 Billion | 3.79x | 16.41x |
| 2025 | $199.73 Billion | $57.13 Billion | $14.65 Billion | 3.50x | 13.63x |
Competitor Companies of NVSEF by Market Capitalization
Companies near Novartis AG in the global market cap rankings as of March 18, 2026.
Key companies related to Novartis AG by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #15 globally with a market cap of $883.37 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #18 globally with a market cap of $574.95 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #29 globally with a market cap of $390.88 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #46 globally with a market cap of $296.35 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #15 | Eli Lilly and Company | NYSE:LLY | $883.37 Billion | $989.12 |
| #18 | Johnson & Johnson | NYSE:JNJ | $574.95 Billion | $243.19 |
| #29 | AbbVie Inc | NYSE:ABBV | $390.88 Billion | $221.45 |
| #46 | AstraZeneca PLC | NASDAQ:AZN | $296.35 Billion | $192.01 |
Novartis AG Historical Marketcap From 2015 to 2025
Between 2015 and today, Novartis AG's market cap moved from $101.00 Billion to $ 199.73 Billion, with a yearly change of 6.48%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $199.73 Billion | +1.92% |
| 2024 | $195.97 Billion | +2.70% |
| 2023 | $190.82 Billion | +19.71% |
| 2022 | $159.40 Billion | +9.48% |
| 2021 | $145.60 Billion | -3.13% |
| 2020 | $150.31 Billion | +2.71% |
| 2019 | $146.35 Billion | +32.28% |
| 2018 | $110.63 Billion | +3.41% |
| 2017 | $106.98 Billion | +21.63% |
| 2016 | $87.96 Billion | -12.92% |
| 2015 | $101.00 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Novartis AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $199.73 Billion USD |
| MoneyControl | $199.73 Billion USD |
| MarketWatch | $199.73 Billion USD |
| marketcap.company | $199.73 Billion USD |
| Reuters | $199.73 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.